An Approved Cancer Drug for Breast Cancer Is Now a Potential New Treatment Option for HER2-Amplified Advanced Salivary Gland Cancer

About “Kadcyla”, Ado-trastuzumab emtansine and HER2-Amplified Advanced Salivary Gland Cancer, SGC - Ado-trastuzumab emtansine, more commonly known as T-DM1 and sold under the trade name “Kadcyla”, is a HER2 targeted antibody-drug…

Continue ReadingAn Approved Cancer Drug for Breast Cancer Is Now a Potential New Treatment Option for HER2-Amplified Advanced Salivary Gland Cancer